Aristides Capital’s Biohaven BHVN Stock Holding History

Aristides Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,298	Closed	-$141K	–	191
2023 Q1	$141K	Hold	10,298	–	–	0.08%	132
2022 Q4	$143K	Buy	+10,298	New	+$145K	0.07%	203

Other funds holding BHVN

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aristides Capital's BHVN Position: Q2 2023 in Review

Aristides Capital sold out of Biohaven (BHVN) in Q2 2023, closing a stake of 10,298 shares — an estimated $141K sold.

Aristides Capital first reported a position in BHVN in Q4 2022 and held it in 2 quarters. The position peaked at $143K in Q4 2022. 188 funds tracked by Wall St. Rank hold BHVN as of Q2 2023.

Aristides Capital reported no remaining Biohaven position as of Q2 2023 after selling out during the quarter.
Aristides Capital sold 10,298 Biohaven shares in Q2 2023, an estimated $141K.
Aristides Capital first reported a position in Biohaven in Q4 2022 and held it in 2 quarters.
Aristides Capital's Biohaven position peaked at $143K in Q4 2022.
188 funds tracked by Wall St. Rank held Biohaven as of Q2 2023.

Based on Aristides Capital's 13F filing for Q2 2023, filed 14 Aug 2023.